Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
作者信息
Moser Carlee B, Li Jonathan Z, Hughes Michael D
机构信息
Harvard T.H. Chan School of Public Health, Boston, MA
Harvard Medical School, Boston, MA.
出版信息
N Engl J Med. 2024 Apr 25;390(16):1533-1534. doi: 10.1056/NEJMc2402378.
Abstract
摘要
相似文献
1
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服Simnotrelvir用于治疗轻至中度新冠肺炎成年患者。
N Engl J Med. 2024 Apr 25;390(16):1533-1534. doi: 10.1056/NEJMc2402378.
2
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服西莫瑞韦用于治疗轻至中度新冠肺炎成年患者。
N Engl J Med. 2024 Apr 25;390(16):1534. doi: 10.1056/NEJMc2402378.
3
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.口服辛诺特韦治疗轻至中度新冠肺炎成年患者。回复。
N Engl J Med. 2024 Apr 25;390(16):1534-1535. doi: 10.1056/NEJMc2402378.
4
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服索那瑞韦治疗成人轻度至中度 COVID-19 患者。
N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425.
5
Simnotrelvir as a potential treatment for COVID-19.西美洛特韦作为一种治疗 COVID-19 的潜在药物。
Expert Opin Pharmacother. 2024 Feb;25(3):233-237. doi: 10.1080/14656566.2024.2323597. Epub 2024 Feb 27.
6
Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study.在中国奥密克戎毒株流行期间，住院的新冠肺炎患者中，西米诺特韦-利托那韦与奈玛特韦-利托那韦的真实世界有效性：一项回顾性队列研究
BMC Infect Dis. 2025 Jul 1;25(1):840. doi: 10.1186/s12879-025-11195-9.
7
Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID-19.西米普明瑞韦/利托那韦和奈玛特韦/利托那韦治疗中度至重度新型冠状病毒肺炎的有效性和安全性
Immun Inflamm Dis. 2025 Apr;13(4):e70174. doi: 10.1002/iid3.70174.
8
Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.辛诺特韦/利托那韦用于治疗新冠肺炎的真实世界有效性和安全性：一项在中国开展的全国性、多中心、前瞻性观察性队列研究。
J Infect. 2024 Dec;89(6):106339. doi: 10.1016/j.jinf.2024.106339. Epub 2024 Nov 7.
9
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.莫努匹拉韦在治疗新冠病毒病中病毒学反应、作用机制生物标志物的暴露-反应关系与临床结局的比较
Clin Transl Sci. 2025 Apr;18(4):e70184. doi: 10.1111/cts.70184.
10
Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.新型SARS-CoV-2抗病毒药物伊布扎特雷韦对成人COVID-19患者的病毒学反应及安全性
Clin Infect Dis. 2025 Mar 17;80(3):673-680. doi: 10.1093/cid/ciae529.
引用本文的文献
1
Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors.作为SARS-CoV-2 3CL蛋白酶抑制剂的拟肽四氢吡咯螺二氢吲哚酮的设计、合成及生物学评价
ACS Med Chem Lett. 2025 Apr 14;16(5):790-796. doi: 10.1021/acsmedchemlett.4c00637. eCollection 2025 May 8.
本文引用的文献
1
Potent new pill provides COVID relief for the masses.
Nature. 2024 Jan;625(7996):644. doi: 10.1038/d41586-024-00117-5.
2
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服索那瑞韦治疗成人轻度至中度 COVID-19 患者。
N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425.
3
Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.用于早期新冠病毒肺炎的口服和静脉注射的1'-氰基取代腺苷类抗病毒药物。
Lancet Infect Dis. 2024 Feb;24(2):108-110. doi: 10.1016/S1473-3099(23)00633-3. Epub 2023 Nov 22.
4
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.在 COVID-19 临床试验中分析低于定量分析检测限的 SARS-CoV-2 RNA 测量值时面临的统计挑战。
J Infect Dis. 2023 Aug 31;228(Suppl 2):S101-S110. doi: 10.1093/infdis/jiad285.
5
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.VV116 对比奈玛特韦片/利托那韦片组合药物用于 COVID-19 口服治疗。
N Engl J Med. 2023 Feb 2;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub 2022 Dec 28.
6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
7
Interpretation of subgroup effects in published trials.发表试验中亚组效应的解读。
Phys Ther. 2013 Jun;93(6):852-9. doi: 10.2522/ptj.20120296. Epub 2013 Feb 21.
8
Interaction 3: How to examine heterogeneity.互动3：如何检验异质性。
BMJ. 1996 Oct 5;313(7061):862. doi: 10.1136/bmj.313.7061.862.
Zotero 插件